Sichuan Cunde Therapeutics Co., Ltd
康德赛
Sichuan Cunde Therapeutics Co., Ltd
Biotech/Healthcare
Kangdesai develops personalized cancer immunotherapies, focusing on a tumor neoantigen-based immunotherapy platform. It has independently developed three proprietary neoantigen-based oncology drug pipelines and an innovative pipeline targeting liver cirrhosis, with the goal of helping patients…
Latest round: Series A (2025)
Source: ChinaBulls — chinabulls.com
Last updated 2025-10-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.